Hartline Investment Corp Sells 306 Shares of Zoetis Inc. (NYSE:ZTS)

Hartline Investment Corp lessened its position in Zoetis Inc. (NYSE:ZTS) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,894 shares of the company’s stock after selling 306 shares during the period. Zoetis comprises about 0.8% of Hartline Investment Corp’s portfolio, making the stock its 25th largest holding. Hartline Investment Corp’s holdings in Zoetis were worth $4,913,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Blue Bell Private Wealth Management LLC boosted its holdings in shares of Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the period. Moisand Fitzgerald Tamayo LLC boosted its holdings in shares of Zoetis by 105.5% during the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after buying an additional 96 shares during the period. Independence Bank of Kentucky boosted its holdings in shares of Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after buying an additional 130 shares during the period. Ramirez Asset Management Inc. bought a new stake in shares of Zoetis during the 3rd quarter worth about $35,000. Finally, First Financial Corp IN boosted its holdings in shares of Zoetis by 57.2% during the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after buying an additional 79 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.9 %

NYSE ZTS traded up $1.32 on Wednesday, hitting $150.88. 3,621,901 shares of the stock were exchanged, compared to its average volume of 3,074,906. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The stock has a fifty day moving average price of $173.78 and a two-hundred day moving average price of $179.78. The firm has a market capitalization of $69.01 billion, a P/E ratio of 29.75, a P/E/G ratio of 2.22 and a beta of 0.85. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the prior year, the company earned $1.15 EPS. Zoetis’s quarterly revenue was up 8.5% on a year-over-year basis. Research analysts forecast that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 1.15%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is currently 34.12%.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Barclays reduced their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday. Stifel Nicolaus decreased their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Piper Sandler reiterated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group increased their price objective on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $218.00.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 363 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now owns 20,417 shares in the company, valued at $4,037,257.58. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 2,209 shares of company stock valued at $371,293. 0.15% of the stock is currently owned by insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.